1. Personal and Professional Experience with GBS Disease
Professionally, my engagement with GBS disease is from a health systems and economic perspective. The most pressing observation is the stark contrast between the availability of interventions and their implementation. Studies show that maternal GBS immunization could be a cost-effective intervention in Nigeria, with a cost-effectiveness ratio (about $320-$350 per DALY averted) similar to other recently introduced vaccines. However, this evidence is meaningless without robust surveillance to identify high-burden populations and the infrastructure to deliver the intervention. My work consistently highlights the disconnect between clinical evidence and systemic capability, a gap that defines the GBS challenge in Nigeria.
2. The Situation in Nigeria
The situation is one of a hidden epidemic with several key characteristics:
- Substantial but Unclear Burden: We know GBS colonization is common, affecting approximately 1 in 8 pregnant women, with higher rates in the South (13%) compared to the North (9%). Neonatal colonization is even higher at 16%, and the risk of invasive disease, though reported as 3%, is likely underreported.
- Data Gaps are the Norm: The lack of surveillance in 19 states is not just a data problem; it is a barrier to resource allocation, policy formulation, and evidence-based advocacy.
- Fragile Health System: Our antenatal care (ANC) coverage is inadequate. With only about 50% of pregnant women attending four or more ANC visits, the platform for delivering interventions like screening or vaccination is already compromised.
3. Reducing the Burden of GBS Disease: An Economist's View
From a health economics standpoint, reducing the GBS burden requires a multi-pronged, cost-effective strategy.
- Strengthen the Surveillance System: This is our most cost-effective initial investment. We cannot manage what we do not measure. We must expand surveillance to all 36 states, using standardized protocols to generate actionable data on incidence, serotypes (like V and II), and antimicrobial resistance. This data is the bedrock for policy.
- Invest in Prevention: The Case for Maternal Vaccination: Intrapartum antibiotic prophylaxis (IAP) is logistically challenging and expensive to implement at scale in Nigeria due to the need for universal screening and timely administration during labor. A maternal vaccine delivered during routine ANC visits is the most promising intervention. Economic modeling confirms that maternal GBS immunization would be a highly cost-effective intervention, potentially preventing one-third of GBS cases and deaths in Nigeria.
- Integrate with Existing Programs: Any new intervention must be integrated into existing maternal and child health platforms. This reduces costs and leverages existing community health structures for delivery and follow-up.
- Address the Treatment Gap: For neonates who develop invasive disease, access to quality care is limited. This includes strengthening neonatal intensive care units (NICUs) and ensuring access to essential antibiotics. The situation for Guillain-Barré Syndrome (GBS), a severe neurological condition that can follow infection and requires costly therapeutic plasma exchange (TPE), is a warning. The rarity of TPE use in Nigeria is a classic example of a severe access gap driven by cost and lack of expertise.
4. What Parents Need to Know and What is the Current Awareness
Parents need to know that GBS is a common bacterium that can be carried without any symptoms but poses a serious risk to newborns, causing sepsis, pneumonia, and meningitis.
The Current Situation: Awareness is critically low. A study on newborn screening, which can be a proxy for broader health awareness, found that 57.2% of caregivers were not aware of the screening tests available.
How to Improve:
- Community Health Education: Use existing platforms like antenatal and immunization clinics to educate pregnant women about GBS, its risks, and prevention strategies.
- Address Cultural Barriers: We must develop culturally sensitive messages in local languages to overcome potential fears and misconceptions. Overcoming these barriers is crucial for the success of any new health intervention.
- Empower with Simple Messages: A simple, clear message that GBS is a common, treatable condition can be the most powerful tool. This is a significant improvement over the current situation where many mothers receive inadequate or no information.
5. What Health Workers Need to Know and What is the Current Awareness
Health workers are the frontline defense. They need to know the epidemiology of GBS in Nigeria, the risk factors for neonatal disease, and the protocols for prevention and treatment.
The Current Situation: While health workers typically have higher awareness than the public (e.g., 73.6% awareness for sickle cell screening), there is still a significant gap in clinical knowledge. Many healthcare workers have not been trained on GBS-specific protocols and may not be recommending preventive measures. The healthcare provider's awareness is crucial for successful vaccination.
How to Improve:
- Mandatory Continuing Education: Integrate GBS prevention and management into the mandatory continuing professional development (CPD) programs for doctors, nurses, and midwives.
- Simplify Clinical Guidelines: Develop and disseminate clear, concise, Nigeria-specific clinical guidelines on screening, IAP, and the management of neonatal sepsis.
- Champion a Culture of Inquiry: Health workers must be trained to ask about GBS and to advocate for surveillance and vaccination.
6. Common Myths about GBS Disease and How to Address Them
Myths, especially in the absence of clear information, can be dangerous.
Myth: It's a rare disease. Reality: Colonization is common (12-13%), but awareness of the condition is not.
Myth: There's nothing you can do. Reality: Interventions like IAP and future vaccines are highly effective.
Myth: It's a 'foreign' disease. Reality: GBS is a significant health problem in Nigeria, and our local serotypes (like V and II) are already being identified.
Myth: Vaccines are dangerous. Reality: The evidence for maternal GBS vaccines is positive, with mostly non-severe adverse events, and they are cost-effective.
How to Address Them:
- Data-Driven Advocacy: Use the meta-analysis data on prevalence to counter the rare disease myth.
- Leverage Trusted Voices: Engage religious and community leaders to deliver accurate messages.
- Utilize Mass Media: Launch public awareness campaigns on radio and TV, which have a wide reach in Nigeria.
- Evidence-Based Communication: Frame the vaccine discussion around its potential to prevent severe illness and death, emphasizing its cost-effectiveness and safety profile.
In conclusion, the battle against GBS in Nigeria is not just a clinical challenge; it is a systemic and economic one. Our path forward must begin with robust data, then proceed with wise investment in cost-effective preventive strategies like maternal vaccination, all while empowering both parents and health workers with the knowledge to act. The economic case is clear; the question is one of political will and health system strengthening.
--
Department of Agricultural Economics,
Faculty of Agriculture
Adekunle Ajasin University
PMB 001,
Akungba Akoko,
Ondo State, Nigeria